恩杂鲁胺对生化复发前列腺癌患者性活动的影响:EMBARK 研究患者报告结局的事后分析
EMBARK 研究显示,高危生化复发前列腺癌患者接受恩杂鲁胺单药或恩杂鲁胺联合亮丙瑞林治疗较单用亮丙瑞林延长无转移生存且健康相关生活质量维持。本事后分析评估性活动相关生活质量,恩杂鲁胺单药较单用亮丙瑞林延迟多项性活动条目确认的临床意义恶化时间,联合治疗与单用亮丙瑞林除勃起功能外相似。
要点
- 恩杂鲁胺单药较单用亮丙瑞林延迟性兴趣、性活动程度、性生活满意度及勃起功能的确认临床意义恶化时间。
- 恩杂鲁胺联合亮丙瑞林与单用亮丙瑞林的性活动相关生活质量恶化时间相似,仅勃起功能中位短 0.1 个月(3 天),无临床意义。
- 各治疗组从基线至第 205 周均未观察到性活动相关条目的临床意义变化。
核心结论
- 恩杂鲁胺单药治疗对性活动相关生活质量的保存在数值上似乎优于单用亮丙瑞林。
研究设计与样本
- EMBARK 研究的事后分析,对性活动相关健康相关生活质量进行条目水平分析。
- 健康相关生活质量在基线及每 12 周评估一次,直至转移或死亡。
- 采用 Cox 回归分析确认的临床意义恶化时间(TTCD,于下次访视确认),采用混合模型重复测量分析纵向变化。
主要发现
- 与单用亮丙瑞林相比,恩杂鲁胺单药延迟性兴趣的 TTCD(8.5 vs 5.6 个月;HR 0.70,95%CI 0.57-0.87;p < 0.001)。
- 与单用亮丙瑞林相比,恩杂鲁胺单药延迟性活动程度的 TTCD(5.7 vs 3.0 个月;HR 0.69,95%CI 0.54-0.90;p = 0.004)。
- 与单用亮丙瑞林相比,恩杂鲁胺单药延迟性生活满意度的 TTCD(11.1 vs 5.4 个月;HR 0.61,95%CI 0.45-0.84;p = 0.001)。
- 与单用亮丙瑞林相比,恩杂鲁胺单药延迟勃起功能的 TTCD(5.5 vs 2.9 个月;HR 0.67,95%CI 0.50-0.88;p = 0.003)。
- 恩杂鲁胺联合亮丙瑞林与单用亮丙瑞林的性活动相关生活质量 TTCD 相似,但勃起功能 TTCD 中位短 0.1 个月(3 天),差异有统计学意义但无临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
EMBARK demonstrated prolonged metastasis-free survival with enzalutamide ± leuprolide versus leuprolide alone for patients with high-risk biochemical recurrence of prostate cancer, with health-related quality of life (HRQoL) maintained. To evaluate treatment effects on sexual activity (SA), item-level analyses of SA-related HRQoL were performed. HRQoL was assessed (baseline, every 12 wk) until metastasis or death. Time to confirmed clinically meaningful deterioration (TTCD; confirmed at next visit) and longitudinal changes in HRQoL were examined using Cox regression and mixed-model repeated measures analyses, respectively. In comparison to leuprolide alone, enzalutamide monotherapy delayed TTCD in interest in sex (8.5 vs 5.6 mo; hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.57-0.87; p < 0.001), extent of SA (5.7 vs 3.0 mo; HR 0.69, 95% CI 0.54-0.90; p = 0.004), satisfaction with sex life (11.1 vs 5.4 mo; HR 0.61, 95% CI 0.45-0.84; p = 0.001), and erectile function (5.5 vs 2.9 mo; HR 0.67, 95% CI 0.50-0.88; p = 0.003). TTCD in SA-related HRQoL was similar with enzalutamide + leuprolide and leuprolide alone, except TTCD in erectile function was shorter by a statistically significant median of 0.1 mo (3 d), which is not clinically meaningful. Longitudinally, no clinically meaningful changes for any SA-related item were observed from baseline to week 205 in any group. SA-related HRQoL preservation seems to be better with enzalutamide monotherapy than with leuprolide alone.
引用
- Freedland SJ, Mulhall JP, Gleave M, et al. Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. Eur Urol. 2025. PMID: 40016055. doi:10.1016/j.eururo.2025.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。